Prolysis Ltd
Prolysis is exploiting unique insights into bacterial cell biology to create the new antibiotics that are urgently needed to treat resistant hospital and community-acquired infections. These products have a sales potential of $200m-$1bn per year.
The company identifies novel chemical starting points that work inside the bacterial cell using patented, highly-sensitive target-selective assays. This overcomes a key hurdle associated with traditional antibiotic discovery techniques. The combination of proprietary, biochemical and antibacterial assays, complemented with antibacterial focused chemistry and drug design creates a unique drug discovery engine.
Prolysis technology has been successfully validated and has delivered medicinal chemistry programmes with the potential to deliver multiple drug candidates.
The cost-effective business model combines internal expertise in bacterial cell biology with structural biology, chemoinformatics and medicinal chemistry from technology partners which has created a multi-project preclinical portfolio. Prolysis will commercialise its new antibiotics by out-licensing after demonstrating proof-of-concept in human studies.